Journal Scans
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bevacizumab Improved Response in HER2-Negative Breast Cancer
H Bear, G Tang, P Rastogi, C Geyer, Jr., A Robidoux, J Atkins, L Baez-Diaz, A Brufsky, R Mehta, L Fehrenbacher, J Young, F Senecal, R Gaur, R Margolese, P Adams, H Gross, J Costantino, S Swain, E Mamounas, N Wolmark
20120026
2012 Jan 26
N Engl J Med
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
N Engl J Med. 2012 Jan 26;366(4):310-320, H Bear, G Tang, P Rastogi, C Geyer, Jr., A Robidoux, J Atkins, L Baez-Diaz, A Brufsky, R Mehta, L Fehrenbacher, J Young, F Senecal, R Gaur, R Margolese, P Adams, H Gross, J Costantino, S Swain, E Mamounas, N Wolmark
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Two studies in the January 26, 2012, issue of the New England Journal of Medicine looked at neoadjuvant chemotherapy plus bevacizumab in patients with early human epidermal growth factor receptor 2 (HER2)–negative breast cancer.Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A and has antiangiogenic effects. In patients with metastatic breast cancer, the addition of bevacizumab or antimetabolites, such as gemcitabine or capecitabine, to taxanes has resulted in improved...
